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E-mail: pbcpsc@kenroku.kanazawa-u.ac.jpPolycomb group protein EZH2, frequently overexpressed in malig-
nant tumors, is the catalytic subunit of polycomb repressive com-
plex 2 (PRC2). PRC2 interacts with HDACs in transcriptional
silencing and relates to tumor suppressor loss. We examined
the expression of HDAC isoforms (HDAC 1 and 2) and EZH2, and
evaluated the possible use of HDAC inhibitor suberoylanilide
hydroxamic acid (SAHA) and EZH2 repressor for gallbladder carci-
noma. We used 48 surgically resected gallbladders and cultures of
human gallbladder epithelial cells (HGECs), gallbladder carcinoma
(TGBC2TKB), and cholangiocarcinoma (HuCCT-1 and TFK-1) cell
lines for examination. Immunohistochemically, EZH2 was overex-
pressed in gallbladder carcinoma, especially poorly differentiated
carcinoma, but not in normal epithelium. In contrast, HDAC1/2
were expressed in both carcinoma and normal epithelium in vivo.
This pattern was verified in cultured cells; EZH2 was highly
expressed only in TGBC2TKB, whereas HDAC1/2 were expressed in
HGECs and TGBC2TKB. Interestingly, SAHA treatment caused sig-
nificant cell number decline in three carcinoma cells, and this effect
was synergized with EZH2 siRNA treatment; however, HGECs were
resistant to SAHA. In TGBC2TKB cells, the expression of EZH2 and
HDAC1/2 were decreased by SAHA treatment, and p16INK4a,
E-cadherin, and p21 were simultaneously activated; however,
no such findings were obtained in HGECs, suggesting that the
effect of SAHA depends on the EZH2-mediated tumor suppressor
loss. In conclusion, this study suggests a possible mechanism by
which carcinoma cells but not normal cells are sensitive to SAHA
and indicates the efficacy of this new anticancer agent in combina-
tion with EZH2 repression in gallbladder carcinoma. (Cancer Sci
2010; 101: 355–362)
G allbladder carcinoma is an aggressive and depressing dis-ease, particularly affecting older people and women.(1–3)
It is usually difficult to detect gallbladder carcinoma in the early
stage, because characteristic signs or symptoms are lacking and
high risk factors have not been established in a majority of
patients. Although complete surgical resection is the only cura-
tive therapy, invasion to surrounding organs or metastases is
usually found in a majority of gallbladder carcinoma patients at
the time of diagnosis. The current chemotherapy for patients
with advanced gallbladder carcinoma is limited, and the devel-
opment and exploration of new anticancer agents is neces-
sary.(4,5)
Polycomb group proteins are epigenetic chromatin modifiers
involved in cancer development.(6,7) PcG proteins exist in at
least two separate protein complexes, polycomb repressive com-
plex 2 (PRC2) and PRC1. The PRC2 complex involves embry-
onic ectoderm development and EZH2.(8,9) EZH2 is a
transcriptional repressor involved in controlling cell growth anddoi: 10.1111/j.1349-7006.2009.01387.x
ª 2009 Japanese Cancer Associationproliferation and an abnormal expression of EZH2 may be
involved in the tumorigenesis process and provides proliferative
advantages to eukaryotic cells through interaction with the path-
ways of key elements that control cell growth arrest and differ-
entiation.(10,11) In addition, various studies have identified EZH2
as a potential marker to distinguish aggressive from indolent or
benign cancers.(12–15)
PRC2 is known to interact with HDAC proteins.(8,9) Recent
studies have disclosed that HDACs have many protein substrates
involved in the regulation of gene expression, cell proliferation,
and cell death. Acetylation and deacetylation of histones play an
important role in the transcription regulation of cells,(16,17) and
the acetylation status of histones and non-histone proteins is
determined by HDACs.(18) Inhibition of HDACs causes the
accumulation of acetylated forms of these proteins with altera-
tions of their function, and the CDK inhibitor p21 (WAF ⁄CIP1)
is one of the most common genes induced by HDAC inhibitor.(4)
In human cells, PRC2 interacts with class I HDAC, which
includes HDAC1 and 2,(8,9,18) and recent data suggest that tran-
sient interactions likely provide functional synergy between the
silencing enzymes for tumor suppressor genes in vivo. The pre-
cise mechanisms of this synergy are not yet clear. Functional
links between EZH2 and HDACs contribute to an emerging
view that all of these types of epigenetic silencing machinery
contribute to abnormal control of gene expression in malignant
cells.
HDAC inhibitors are a group of recently discovered targeted
anticancer agents. HDAC inhibitors induce different phenotypes
in various transformed cells, including growth arrest, activation
of extrinsic and ⁄or intrinsic apoptotic pathways, autophagic
cell death, mitotic cell death, and senescence.(19) In comparison,
normal cells are relatively more resistant to HDAC inhibitor-
induced cell death;(20,21) however, the mechanism underlying
this difference is not well understood.
Among HDAC inhibitors, SAHA is one of the most advanced
in clinical fields as an anticancer agent, which interacts directly
with the catalytic site of HDAC-like protein and inhibits its
enzymatic activity.(18) SAHA inhibits all 11 members of the
class I and II HDAC family, and causes specific modifications in
the pattern of acetylation and methylation of lysines in histones
H3 and H4 associated with the proximal promoter of the p21
gene.(18) Although considerable progress has been made in elu-
cidating the role of HDACs and the effects of HDAC inhibitors,
these areas are still in the early stages of discovery.
Several previous studies reported abnormal promoter methyl-
ation of important genes including p16INK4a and E-cadherin
in gallbladder carcinoma,(22,23) however, there have been fewCancer Sci | February 2010 | vol. 101 | no. 2 | 355–362






Mean ± SD (range) Male:female
Cholecystolithiasis
without BilIN-1 ⁄ 2
10 61.0 ± 14.6 (38–81) 7:3
Gallbladder cancer 38 77.1 ± 8.3 (57–90) 16:22
Papillary
adenocarcinoma
7 77.4 ± 3.4 (60–90) 3:4
Well differentiated
adenocarcinoma
9 73.2 ± 3.2 (57–88) 5:4
Moderately differentiated
adenocarcinoma
12 79.3 ± 1.5 (72–85) 5:7
Poorly differentiated
adenocarcinoma
10 78.9 ± 3.6 (65–90) 3:7
BilIN-1 ⁄ 2, biliary intraepithelial neoplasm-1 ⁄ 2.studies addressing alteration of epigenetic chromatin modifica-
tion by PcG and HDACs in gallbladder carcinoma.(24,25) In this
study using human gallbladders and cultures of gallbladder epi-
thelial cells and the gallbladder carcinoma cell line, we assessed
the expression pattern of EZH2 and class I HDACs (HDAC 1
and 2). We considered the possible mechanism by which carci-
noma cells are sensitive to SAHA and the possible efficacy of
this new anticancer agent in therapeutic treatment in gallbladder
carcinoma.
Materials and Methods
Human tissue studies. Preparation of tissue specimens.
Forty-eight surgically resected gallbladders were used, 10
with cholecystolithiasis and chronic cholecystitis, which were
used as a control, and 38 with gallbladder carcinoma
(Table 1). Gallbladder carcinoma consisted of 9 well differen-
tiated, 12 moderately differentiated, and 10 poorly differenti-
ated adenocarcinomas, and 7 papillary adenocarcinomas. All
surgically resected gallbladders were fixed in 10% formalin.
After embedding in paraffin, approximately 20 serial thin sec-
tions were cut from each block, and used for histological and
immunohistochemical analyses. This study was approved by
the Ethics Committee of Kanazawa University (Kanazawa,
Japan).
Immunohistochemistry. The expression of EZH2, HDAC1, and
HDAC2 were assessed immunohistochemically using monoclo-
nal antibodies: anti-EZH2 (clone 11, 1:100; BD Transduction
Laboratories, San Jose, CA, USA); anti-HDAC1 (clone 3E1,
1:250; Sigma, St Louis, MO, USA); and anti-HDAC2 (ab12169,
1:500; Abcam, Cambridge, UK), as described previously.(6,24)
As a negative control, similar dilution of the control mouse IgG
(Dako, Glostrup, Denmark) was applied.
The expressions of EZH2, HDAC1, and HDAC2 were evalu-
ated semiquantitatively according to the percentage of positive
cells: 1 (negative, 0–10% epithelial cells in the lesion were posi-
tive); 2 (focal, 10–50% positive); and 3 (extensive, 50–100%
positive). In addition, the percentage of cells positive for EZH2
was semiquantitatively calculated in high-power fields of two or
three foci containing approximately 100 contiguous epithelial
cells, and the mean was regarded as the labeling index in each
case.
Cell culture study. Reagents. SAHA was purchased from
Cayman Chemical (Ann Arbor, MI, USA). Media, FBS, and
antibiotic–antimycotic were purchased from Gibco (Rockville,
MD, USA).356Primary culture of HGECs. Human gallbladder epithelial cells
were established from a surgically resected gallbladder with
cholecystolithiasis as described,(24,26) and grown as monolayers.
Epithelial nature of these cells was confirmed by the expression
of CK7. HGECs were incubated in culture medium as
described, and HGECs between passages four and eight were
used.
Culture of carcinoma cell line. The human gallbladder carci-
noma cell line TGBC2TKB (RCB1130) was provided by the
Riken Cell Bank (Tsukuba, Japan). Two human cholangiocarci-
noma cell lines, HuCCT-1 and TFK-1, were provided by Cell
Resource Center for Biochemical Research, Tohoku University,
Sendai, Japan. TGBC2TKB cells were maintained in DMEM
containing 5% FBS, and HuCCT-1 and TFK-1 in RPMI-1640
with 10% FBS in a standard condition.
Assay for relative cell number. Carcinoma cells (TGBC2TKB,
HuCCT-1, and TFK-1) and HGECs were seeded in a 96-well
plate (3–5 · 103 cells per well). After several treatments,
these cells were cultured for 48 h and the relative cell num-
ber was assessed using Cell Proliferation Reagent WST-1
according to the manufacturer’s protocol (Roche, Mannheim,
Germany).
Assay for apoptosis. Apoptosis was detected using the ssDNA
apoptosis ELISA kit (Millipore, Billerica, MA, USA) according
to the manufacturer’s protocol.
Western blot analysis. Western blotting was carried out using a
standard method.(6,24) The membrane was incubated with pri-
mary antibodies against EZH2 (1:500), HDAC1 (1:500),
HDAC2 (1:500), p21 (Cip1 ⁄WAF1, clone 70, dilution 1:100;
BD Transduction Laboratories), p16INK4a (clone JC8, dilution
1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
E-cadherin (clone 36 ⁄E-cadherin, dilution 1:100; BD Transduc-
tion Laboratories), and b-actin (1:5000; Abcam).
RT-PCR. RT-PCR was carried out using a standard
method.(6,24) The annealing temperature was 54C for EZH2,
HDAC1, and HDAC2, and 56C for G3PDH. The number of
PCR cycles was 27 for EZH2, and 35 for HDAC1 and HDAC2.
Primer sequences were as follows: EZH2, 5¢-gtggagagattatttc-
tcaagatg-3¢ and 5¢-ccgacatacttcagggcatcagcc-3¢; HDAC1, 5¢-agc-
caagagagtcaaaacaga-3¢ and 5¢-ggtccattcaggccaact-3¢; HDAC2,
5¢-gagcaatgcggagaaatgtt-3¢ and 5¢-tgctctgcttgttacatggc-3¢; and
G3PDH, 5¢-gaacgggaagctcactggcatggc-3¢ and 5¢-tgaggtccacca-
ccctgttgctg-3¢.
Quantitative real-time PCR. Quantitative real-time PCR was
carried out to measure HDAC1, HDAC2, and G3PDH mRNA
according to a standard protocol using the SYBR Green PCR
Master Mix (Toyobo, Tokyo, Japan) and an ABI Prism 7700
sequence detection system (Applied Biosystems, Tokyo, Japan).
Fold difference in comparison with the control was calculated.
Each experiment was carried out in triplicate, and the mean was
adopted in each experiment.
Knockdown of EZH2 by siRNA. Validated siRNA for EZH2
and negative control siRNA were purchased from Santa Cruz
Biotechnology and Qiagen (Hilden, Germany), respectively.
One day before transfection, cells were plated in 12-well plates
(3–5 · 104 cells), then transiently transfected with either EZH2
or control siRNA (100 nM), using Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA, USA), according to the manufacturer’s
protocol.
ChIP assay. We examined the effect of EZH2 knockdown and
SAHA on the interaction and chromatin modification of the
p16INK4a and E-cadherin promoter in TGBC2TKB cells. ChIP
assay was carried out using an EZ ChIP kit (Upstate, Lake pla-
cid, NY, USA) according to the manufacturer’s protocol. Anti-
bodies specific for trimethyl histone H3-Lys27 (TM-H3K27;
Upstate) and acetyl H3-Lys27 (Ac-H3K27; Upstate), EZH2
(described above) and normal mouse or normal rabbit IgG as adoi: 10.1111/j.1349-7006.2009.01387.x
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control were used for immunoprecipitation. PCR was carried
out using the following pairs of primers:(27,28) p16INK4a, 5¢-
ggctagttttatgaccaagacg-3¢ and 5¢-gaggstggtggtgttaaagagg-3¢;
E-cadherin, 5¢-tagagggtcaccgcgtctat-3¢ and 5¢-tcacaggtgctttg-
cagttc-3¢; and GAPDH, 5¢-ggtagggagttcgagaccag-3¢ and
5¢-tcaacgcagttcagttaggc-3¢.
Statistical analysis. Data are expressed as the mean ± SD. For
comparisons of multiple groups, we used Welch’s t-test. Differ-
ences and v2-test with values of P < 0.05 were considered
significant.
Results
Human tissue studies. Immunohistochemical expression of
EZH2. EZH2 was expressed in the nuclei of non-neoplastic
epithelial cells and carcinoma cells, when detectable (Fig. 1).
EZH2 expression was clear and frequent in carcinoma, but faint
and infrequent in non-neoplastic epithelium of chronic chole-
cystitis. EZH2 expression was more extensive in gallbladder
carcinoma than in chronic cholecystitis (Fig. 2a) (P < 0.05).
In gallbladder carcinoma, EZH2 expression was higher in
poorly differentiated adenocarcinoma than in other histological
types of gallbladder carcinoma, including well and moderately
differentiated adenocarcinoma and papillary adenocarcinoma
(Fig. 2b).
Immunohistochemical expressions of HDAC1 and HDAC2.
HDAC1 and HDAC2 were expressed in the nuclei of non-
neoplastic epithelial cells and carcinoma cells in both chronic
cholecystitis and gallbladder carcinoma (Fig. 1). There were no(a)
(c)
(e)
Fig. 1. Immunohistochemical expression of poly-
comb group protein EZH2 (a,b), histone deacetylase
(HDAC) 1 (c,d), and HDAC2 (e,f) in chronic
cholecystitis (left) and gallbladder carcinoma (right).
EZH2 is expressed in the nuclei of gallbladder
epithelium and carcinoma. EZH2 is overexpressed in
gallbladder carcinoma in comparison with chronic
cholecystitis. HDAC1 and HDAC2 are expressed in
the nuclei of gallbladder epithelium and carcinoma,
and also in the stromal cells of chronic cholecystitis
and gallbladder carcinoma. Nuclear staining of
HDAC1 and HDAC2 is slightly stronger in gallblad-
der carcinoma than in non-neoplastic gallbladder
epithelium. Original magnification, ·200.
Yamaguchi et al.differences in the extent of HDAC1 and HDAC2 expressions
between chronic cholecystitis and gallbladder carcinoma
(Fig. 2a), although nuclear staining was slightly weaker in non-
neoplastic epithelial cells than in carcinoma cells. Interestingly,
HDAC1 and HDAC2 were also expressed in non-epithelial cells
such as fibroblasts and smooth muscle cells in the stroma of the
gallbladder (Fig. 1).
Cell culture studies. Expression patterns of EZH2 and
HDACs in cultured cells. The expression of EZH2 and HDACs
was examined in cultured normal gallbladder epithelial cell
(HGECs) and gallbladder carcinoma cell (TGBC2TKB) by RT-
PCR and Western blotting. RT-PCR showed EZH2 mRNA
expression in carcinoma cells, but not in HGECs (Fig. 3a).
HDAC1 and 2 were expressed in both HGECs and TGBC2TKB
cells, and real-time PCR showed that their expression levels
were two- or threefold higher in TGBC2TKB cells (P < 0.01)
(Fig. 3b). Similarly, Western blotting showed HDAC1 and 2 in
both HGECs and TGBC2TKB cells, and its expression levels
were slightly higher in TGBC2TKB cells (Fig. 3c).
Effect on cell number of cultured cells by SAHA and EZH2
siRNA. To evaluate the effect of SAHA and EZH2 treatment on
the proliferation of cultured cells, EZH2 siRNA or control siR-
NA was first transfected in HGECs, TGBC2TKB, HuCCT-1,
and TFK-1 cells, then these cultured cells were treated with
1.0 lM SAHA for 48 h. Relative cell number was calculated by
WST-1 assay (Fig. 4a). It was found that EZH2 siRNA and
SAHA treatment induced a relative reduction of TGBC2TKB,
HuCCT-1, and TFK-1 cells (P < 0.01), and furthermore, the
combination of these treatments induced a synergistic effect in(b)
(f)
(d)
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(a)
(b)
Fig. 2. (a) Frequency and degree of immuno-
histochemical expression of polycomb group protein
EZH2, histone deacetylase (HDAC) 1, and HDAC2 in
chronic cholecystitis (CCL) and gallbladder cancer
(GBCa). EZH2 expression is extensive in GBCa in
comparison with CCL (P < 0.05), whereas HDAC1 and
HDAC2 is expressed similarly in CCL and GBCa. N.S.,
not significant. (b) Labeling index (LI) of the
expression of EZH2 in gallbladder carcinoma. Poorly
differentiated adenocarcinomas (Por) have a higher
labeling index of EZH2 (LI, 70.5 ± 20.7%) than other
histological types of carcinoma (LI of papillary
adenocarcinoma [Pap], 51.4 ± 21.5%; LI of well
differentiated adenocarcinoma [Well], 50.6 ± 8.8%;
LI of moderately differentiated adenocarcinoma
[Mod], 51.2 ± 23.8%). n, number of cases. *P < 0.05.the relative reduction of cell numbers (P < 0.01), suggesting
that TGBC2TKB, HuCCT-1, and TFK-1 cells are sensitive to
EZH2 siRNA and SAHA treatment. However, these treatments
had no effect on the relative number of HGECs. Considering the
expression status of EZH2 and HDACs in HGECs, SAHA treat-
ment had no effect on the number of cultured HGECs, suggest-
ing that HGECs were also resistant to SAHA treatment in spite
of their HDAC expression.
Effect on apoptosis of cultured cells by SAHA and EZH2
siRNA. To evaluate the effect of SAHA and EZH2 treatment
on apoptosis of cultured cells, EZH2 siRNA or control siRNA
was first transfected in TGBC2TKB cells, then these cultured
cells were treated with 1.0 lM SAHA for 48 h. Apoptosis was
detected using the ssDNA apoptosis ELISA kit (Fig. 4b). It
was found that combined treatment of SAHA and EZH2
siRNA tended to induce a slight increase of apoptosis in
TGBC2TKB cells, but there was no significant difference.
This finding suggests that apoptosis might not be related to
the synergistic effect of combined treatment of SAHA and
EZH2 siRNA on relative reduction of cell numbers and that
other processes, probably cell cycle arrest, may be responsible
for the synergistic effect.
Effect of SAHA on HDAC expression in cultured cells. To
understand the mechanism of the different effects of SAHA in
the two types of cultured cells, the expression levels of EZH2
and HDACs in cultured cells treated by EZH2 siRNA and ⁄or
SAHA were assayed by Western blotting (Fig. 5a). EZH2
siRNA or control siRNA was transfected in HGECs and
TGBC2TKB cells, then treated with SAHA (1.0 lM for 48 h).
The EZH2 level increased in TGBC2TKB cells was consider-
ably reduced by EZH2 siRNA, and more by SAHA, and also by358SAHA + EZH2 siRNA. HDACs levels were repressed by
SAHA treatment, and this repression was seen in both HGECs
and TGBC2TKB cells almost equally. This indicates that the
reduction of HDACs alone is not the cause of the SAHA treat-
ment effect, because the repression of HDACs in HGECs does
not reflect the resistance to SAHA treatment indicated in the
WST-1 assay. However, SAHA repressed the EZH2 level in
TGBC2TKB cells.
Effect on p16 and E-cadherin expression and chromatin
modification in TGBC2TKB cells. The expression levels of
p16INK4a and E-cadherin in TGBC2TKB cells treated by
EZH2 siRNA and ⁄or SAHA (described above) were assayed
by Western blotting (Fig. 5b). The protein expression level of
p16INK4a and E-cadherin was increased by EZH2 siRNA,
more by SAHA, and also by SAHA and EZH2 siRNA in
TGBC2TKB cells.
ChIP assays showed that the p16INK4a and E-cadherin pro-
moter was bound by EZH2 directly in TGBC2TKB cells
(Fig. 5c). EZH2 binding to the p16INK4a promoter was decreased
by SAHA treatment, whereas acetylated-H3K27 levels increased
at the p16INK4a promoter by SAHA. Trimethylated-H3K27 lev-
els decreased at the p16INK4a promoter by SAHA. The reason
remains unknown why trimethylated-H3K27 levels recovered at
the p16INK4a promoter by combined SAHA and EZH2 siRNA
treatment. EZH2 binding to the E-cadherin promoter was
decreased by combined SAHA and EZH2 siRNA treatment.
Acetylated-H3K27 levels increased at the E-cadherin promoter
by SAHA and ⁄or EZH2 siRNA. Trimethylated-H3K27 levels
decreased at the E-cadherin promoter by SAHA. These findings
suggest that EZH2 binds to the p16INK4a and E-cadherin
promoter and that SAHA and ⁄or EZH2 siRNA treatmentdoi: 10.1111/j.1349-7006.2009.01387.x
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(a) (b) (c)
Fig. 3. Expressions of polycomb group protein EZH2, histone deacetylase (HDAC)1, and HDAC2 in cultured cells. (a) RT-PCR: EZH2 mRNA
expression is clear in carcinoma cells (TGBC2TKB) but negligible in normal human gallbladder epithelial cells (HGECs), and HDAC 1 and 2 mRNA
are clearly expressed in carcinoma cells and normal epithelial cells. (b) Real-time PCR: Expressions of HDAC 1 and 2 mRNA are higher in
carcinoma cells (TGBC2TKB) than in normal HGECs (P < 0.01). (c) Protein expression is evaluated in normal HGECs and gallbladder carcinoma cells
(TGBC2TKB) by Western blot analysis. EZH2 expression is evident in carcinoma cells but is very weak in normal HGECs. HDAC 1 and 2 expressions
are clear in both of these cells, but the expression level is a little lower in normal epithelial cells than in carcinoma cells.
(b)
(a)
Fig. 4. Effect of suberoylanilide hydroxamic acid
(SAHA) and polycomb group protein EZH2 siRNA on
cell proliferation and apoptosis of cultured cells.
After transfection of control siRNA and EZH2 siRNA,
cultured cells were treated with SAHA (1.0 lM for
48 h). (a) Relative cell numbers of normal human
gallbladder epithelial cells (HGECs) are not reduced
by SAHA and ⁄ or EZH2 siRNA treatment. In contrast,
the relative cell numbers of carcinoma cells
(TGBC2TKB) are reduced by SAHA and EZH2 siRNA
treatment (P < 0.01), and this effect is synergized
(P < 0.01). Relative cell number was evaluated
by WST-1 assay. HuCCT-1 and TFK-1 are cholangio-
carcinoma cell lines. (b) Apoptosis of carcinoma
cells (TGBC2TKB) is not significantly increased by
SAHA and EZH2 siRNA treatment (P > 0.01).
Apoptosis was detected using an ssDNA apoptosis
ELISA kit.
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Fig. 5. (a) Effect on polycomb group protein EZH2, histone deacetylase (HDAC) 1, and HDAC2 protein expression in cultured cells by
suberoylanilide hydroxamic acid (SAHA) and EZH2 siRNA treatment. Western blotting: The increased expression of EZH2 in carcinoma cells
(TGBC2TKB) was reduced by SAHA (1.0 lM for 48 h) and EZH2 siRNA treatment, whereas EZH2 was not expressed in normal human
gallbladder epithelial cells (HGECs) before or after treatment. Expression of HDAC 1 in normal cells and carcinoma cells was repressed by
SAHA treatment and also EZH2 siRNA, and HDAC2 expression was repressed in normal cells and carcinoma cells by SAHA treatment, but not
clearly by EZH2 siRNA treatment. C, control siRNA; E, EZH2 siRNA. (b) Effect on p16INK4a (p16) and E-cadherin (E-cad) protein expression in
cultured cells by SAHA and EZH2 siRNA treatment. Western blotting: The expression of p16INK4a and E-cadherin was increased by SAHA
(1.0 lM for 48 h) and EZH2 siRNA treatment in TGBC2TKB cells. C, control siRNA; E, EZH2 siRNA. (c) ChIP assays were carried out using
antibodies against trimethylated histone H3Lys27 (TM-H3K27), acetylated histone H3Lys27 (Ac-H3K27), EZH2, and IgG (control) in TGBC2TKB
cells treated with SAHA (1.0 lM for 48 h) and ⁄ or EZH2 siRNA. PCR was carried out using primers for each amplicon targeting human p16INK4a
(left) and E-cadherin (right) promoter. EZH2 binding to the p16INK4a promoter was decreased by SAHA, whereas Ac-H3K27 levels increased at
the p16INK4a promoter by SAHA. TM-H3K27 levels decreased at the p16INK4a promoter by SAHA. EZH2 binding to the E-cadherin promoter was
decreased by combined SAHA and EZH2 siRNA treatment. Ac-H3K27 levels increased at the E-cadherin promoter by SAHA and ⁄ or EZH2 siRNA.
TM-H3K27 levels decreased at the E-cadherin promoter by SAHA. (d) p21 protein expression in cultured cells by SAHA treatment. Western
blotting: normal HGECs and TGBC2TKB carcinoma cells were treated with SAHA (1.0 lM for 6 h). p21 was detectable (activated) in carcinoma
cells but not in normal epithelial cells.affect trimetylated and acetylated levels at the p16INK4a and
E-cadherin promoter and increase the expression levels of
p16INK4a and E-cadherin.
SAHA induces p21 expression in cultured TGBC2TKB cells
but not in HGECs. We then examined whether tumor suppres-
sor genes are activated by SAHA treatment by evaluating p21
activation in TGBC2TKB cells and HGECs by SAHA treatment
(1.0 lM for 6 h). It was found that p21 was expressed in
TGBC2TKB cells but not in HGECs (Fig. 5d), suggesting that
HDACs are responsible for p21 repression in TGBC2TKB
cells, and that the suppressed p21 gene is re-activated by the
repression of HDACs induced by SAHA. In contrast, in HGECs,
HDACs were not responsible for p21 gene repression and
HDACs inhibition did not activate p21 expression.
Discussion
Chromatin alterations are causally related to the development
and progression of malignant tumors. The most well-character-
ized alteration is CpG DNA hypermethylation, which contrib-360utes to tumor suppressor loss through epigenetic silencing,(29)
and epigenetic modification of histones is also implicated in
oncogenesis.(30) A common biological function of PRC2 is
transcriptional silencing of differentiation genes, and frequent
targets of PRC2 are transcription factors and signaling compo-
nents with key roles in cell fate decisions in a wide variety of
organisms. PRC2 contains a conserved catalytic subunit,
EZH2, which contains the signature domain providing the
methylation active site,(31) and EZH2 levels are abnormally
elevated in malignant tissues, with the highest EZH2 levels
correlating with advanced stages and poor prognosis.(10,12,15)
This study showed that EZH2 was overexpressed in gallblad-
der carcinoma, particularly poorly differentiated carcinoma,
but its expression was faint and infrequent in non-neoplastic
epithelium. Culture studies also showed EZH2 mRNA and
protein expression in gallbladder carcinoma cells, but not in
normal cells. Furthermore, downregulation of EZH2 by siRNA
induces significant growth inhibitory effect in gallbladder car-
cinoma cells and cholangiocarcinoma cells to various degrees.
EZH2 siRNA also increased the expression of E-cadherin,doi: 10.1111/j.1349-7006.2009.01387.x
ª 2009 Japanese Cancer Association
which is supposed to control invasiveness of carcinoma, by
chromatin modification. Taken together, EZH2 may be related
to factors controlling cell proliferation, differentiation, and
invasiveness in gallbladder carcinoma as reported in other
types of cancers.(10–15,27,28)
PRC2 is known to interact with HDAC proteins.(8,9) Recent
studies disclosed that HDACs have many protein substrates
involved in the regulation of gene expression, cell proliferation,
and cell death. Acetylation and deacetylation of histones play an
important role in transcription regulation of eukaryotic
cells.(16,17) Recently, several reports showed that HDACs are
strongly expressed in cancerous tissue, and the expression of
class I HDACs is an independent prognostic marker in various
cancers, such as ovarian, colorectal and cervical cancer.(32–34)
The present study showed that HDAC1 ⁄2 were expressed in the
nuclei of non-neoplastic epithelial cells and carcinoma cells in
the gallbladder, although nuclear staining was slightly weaker in
the former than in the latter. This pattern was verified in cultured
normal epithelial and carcinoma cells, indicating that HDAC1 ⁄2
expression level is a little higher in cancerous tissue;
however, its expression is not specific to carcinoma cells in the
gallbladder.
Both epigenetic changes and genetic alterations to DNA
sequence in the malignant cell genome might contribute to
disease progression. Once the DNA sequence is changed by
mutation, it is difficult to restore the gene; however, epi-
genetic changes can potentially be reserved with inhibitors
that block the relevant chromatin-modifying enzymes. Epi-
genetic silencing of the tumor suppressor gene in carcinoma
has inspired potential therapeutic strategies that use inhibitors
of epigenetic enzymes. Many inhibitors target either DNA
methyltransferases or HDACs.(16) HDAC inhibitors have been
found to have profound anticancer effects in clinical trials.(5)
Among HDAC inhibitors, SAHA is one of the most advanced
in clinical fields as an anticancer agent. SAHA has shown
significant anticancer activity in tumor-bearing animals and in
phases I and II clinical trials with little evidence of adverse
effects on normal cells.(5)
It was found in this study that SAHA treatment reduced the
number of gallbladder carcinoma cells and cholangiocarcinoma
cells, suggesting that carcinoma cells are sensitive to SAHA
treatment. However, this treatment had no effect on the number
of normal epithelial cells in spite of their HDAC expression.
The reason why carcinoma cells are more sensitive to SAHA
compared to normal cells remains speculative. High expression
levels of EZH2 might be related to high sensitivity to SAHA in
carcinoma cells, as discussed below. SAHA significantly
repressed the EZH2 level in carcinoma cells. These differences
in sensitivity to SAHA-induced cell reduction of carcinoma cells
compared with normal cells appeared not to be caused by a dif-
ference in the expression levels of HDACs, because normal cells
and the normal epithelium of the gallbladder has relatively weak
but significant expression levels of HDAC1 ⁄2, and moreover, it
was found that the expression level of HDACs was significantly
repressed in normal cells and also carcinoma cells by SAHA
treatment.
Histone deacetylase inhibitors are known to alter gene
expression followed by the expression of the proteins respon-
sible for composing the transcription factor complex to which
HDACs are recruited.(8,9) We therefore examined whether
tumor suppressor genes are activated by SAHA treatment by
evaluating p21 activation in gallbladder carcinoma cells and
normal cells by SAHA treatment. It was found that p21 was
expressed in carcinoma cells but not in normal cells, indicat-
ing that HDACs forcibly repress the p21 gene in carcinoma
cells, that inhibition of HDACs by SAHA treatment re-acti-
vated the p21 gene, and that HDACs are not responsible for
p21 gene repression in normal cells. One hypothesis is thatYamaguchi et al.p21 is not forcibly repressed in normal epithelial cells, and
HDACs do not act as a p21 gene suppressor; therefore,
HDAC inhibition does not result in activation of the p21
gene in normal cells.
Almost all carcinomas have multiple alterations in the expres-
sion and ⁄or structure of proteins that regulate cell proliferation
and death. The multiple alterations of tumor suppressor genes in
cancer cells might explain why transformed cells are more sensi-
tive than normal cells to the HDAC inhibitor. EZH2 are reported
to mediate tumor suppressor genes, such as p16INK4A and
E-cadherin.(28,35,36) In this context, the effect of HDAC inhibitor
might be linked to EZH2 expression. In the link between EZH2
and HDACs it has been reported that PRC2-mediated transcrip-
tional silencing is impeded by the HDAC inhibitor, trichostatin
A (TSA).(12,15) EZH2 is reported to have a SET domain, which
is responsible for histone methylation, and this activity was
abrogated in the presence of TSA.(12,15,16) Interestingly, the
present study showed that SAHA decreased EZH2 expression
itself in carcinoma cells, in addition to HDAC repression. Simi-
lar downregulation of EZH2 by HDAC inhibitor has been
reported by Fiskus et al.(37) Whether the mechanism by which
HDAC inhibitors such as SAHA deplete EZH2 level is tran-
scriptional, post-transcriptional, or increased protein degradation
remains to be addressed in future study. This double-repression
effect might be an important mechanism in the anticancer effect
of SAHA and the reason why normal cells are resistant to SAHA
treatment. Normal cells express HDAC1 ⁄2 in gallbladder epi-
thelial cells, but not EZH2. Whereas gallbladder carcinoma
cells, which have both HDAC and EZH2 expression, work
together as transcriptional repressors of tumor suppressor genes,
and SAHA repressed these epigenetic enzymes together and
re-activates tumor suppressor genes. From this point of view,
the effect of SAHA on gallbladder carcinoma might be associ-
ated with EZH2 expression, rather than HDAC expression.
As epigenetic enzymes often synergize in vivo, there is also
great interest in testing combined inhibitor treatments that
target more than one epigenetic enzyme, suggesting that combi-
nation of an HDAC inhibitor and other anticancer agents might
be very attractive therapeutic strategies. It was found in this
study that the combination of SAHA and EZH2 siRNA
decreased cell numbers more than either single treatment. It
was disclosed that cell cycle arrest, not apoptosis, might be
related to the synergistic effect of the combined treatment. Fur-
thermore, this study showed that SAHA and ⁄or EZH2 siRNA
treatment affect trimetylated and acetylated levels at the
p16INK4a and E-cadherin promoter and the combined treatment
increased the expression levels of p16INK4a and E-cadherin.
Although the mechanism how the addition of EZH2 siRNA
enhanced antitumor activity of SAHA remains to be clarified,
EZH2 downregulation might affect other members of PRC2(37)
and HDAC activity, which result in the enhanced antitumor
effect of SAHA. Similar to HDACs, EZH2 histone methyl-
transferase has emerged as a key target in potential epigenetic
strategies; however, specific inhibitors of EZH2 histone methyl-
transferase have not been described. The most encouraging
inhibitory agent of PRC2 reported so far is deazaneplanocin A,
which can deplete PRC2 subunits in breast cancer cell lines
and reactivate PRC2-silenced genes.(38) However, as this type
of inhibitor might affect many processes that require methyl
transfer, there are concerns about its specificity in potential
therapy. The availability of histone methyltransferase inhibitors
specific for EZH2, EZH2 inhibitor, and HDAC inhibitor should
expand the repertoire of new possibilities in combined epi-
genetic therapy.
In conclusion, we showed that EZH2 is overexpressed in
carcinoma cells, and HDAC1 ⁄2 were clearly expressed in both
carcinoma cells and normal epithelial cells of the gallbladder.
This expression pattern was also followed in cultured cells.Cancer Sci | February 2010 | vol. 101 | no. 2 | 361
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SAHA treatment reduced the expression levels of HDAC1 ⁄2
and EZH2 in cultured carcinoma cells along with their reduced
cell numbers, and this effect was synergized when treated with
EZH2 siRNA. Because gallbladder carcinoma shows increased
expressions of EZH2 and HDAC1 ⁄2, therapeutic SAHA treat-
ment with EZH2 repressors, such as EZH2-specific methyltrans-
ferase inhibitor, is a promising therapeutic approach in
gallbladder carcinoma.362Abbreviations
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